Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Insights and Forecast to 2028

Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Insights and Forecast to 2028

Table of Contents
1 Study Coverage
1.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Introduction
1.2 Market by Type
1.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 1g/20ml
1.2.3 1.25g/25ml
1.2.4 2.5g/50ml
1.2.5 5g/100ml
1.2.6 10g/200ml
1.3 Market by Application
1.3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Estimates and Forecasts 2017-2028
2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Estimates and Forecasts 2017-2028
2.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region
2.4.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2022)
2.4.2 Global Sales Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Region (2023-2028)
2.5 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region
2.5.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2022)
2.5.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Manufacturers
3.1.1 Global Top Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturers by Sales (2017-2022)
3.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) in 2021
3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Manufacturers
3.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Manufacturers (2017-2022)
3.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue in 2021
3.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type
4.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historical Sales by Type (2017-2022)
4.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecasted Sales by Type (2023-2028)
4.1.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028)
4.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type
4.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historical Revenue by Type (2017-2022)
4.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecasted Revenue by Type (2023-2028)
4.2.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028)
4.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Type
4.3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Type (2017-2022)
4.3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application
5.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historical Sales by Application (2017-2022)
5.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecasted Sales by Application (2023-2028)
5.1.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028)
5.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application
5.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historical Revenue by Application (2017-2022)
5.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecasted Revenue by Application (2023-2028)
5.2.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028)
5.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Application
5.3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Application (2017-2022)
5.3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Forecast by Application (2023-2028)
6 North America
6.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type
6.1.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028)
6.1.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028)
6.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application
6.2.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028)
6.2.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028)
6.3 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country
6.3.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2028)
6.3.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type
7.1.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028)
7.1.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028)
7.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application
7.2.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028)
7.2.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028)
7.3 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country
7.3.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2028)
7.3.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type
8.1.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028)
8.1.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028)
8.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application
8.2.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028)
8.2.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028)
8.3 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Region
8.3.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2028)
8.3.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type
9.1.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028)
9.1.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028)
9.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application
9.2.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028)
9.2.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028)
9.3 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country
9.3.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2028)
9.3.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type
10.1.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028)
10.1.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028)
10.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application
10.2.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028)
10.2.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028)
10.3 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country
10.3.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2028)
10.3.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Boya-Bio
11.1.1 Boya-Bio Corporation Information
11.1.2 Boya-Bio Overview
11.1.3 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Boya-Bio Recent Developments
11.2 Beijing Tiantan Biological Products
11.2.1 Beijing Tiantan Biological Products Corporation Information
11.2.2 Beijing Tiantan Biological Products Overview
11.2.3 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Beijing Tiantan Biological Products Recent Developments
11.3 Hualan Bio
11.3.1 Hualan Bio Corporation Information
11.3.2 Hualan Bio Overview
11.3.3 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Hualan Bio Recent Developments
11.4 Guangdong Shuagnlin Bio-pharmacy
11.4.1 Guangdong Shuagnlin Bio-pharmacy Corporation Information
11.4.2 Guangdong Shuagnlin Bio-pharmacy Overview
11.4.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
11.5 Weiguang Biological
11.5.1 Weiguang Biological Corporation Information
11.5.2 Weiguang Biological Overview
11.5.3 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Weiguang Biological Recent Developments
11.6 Sinopharm
11.6.1 Sinopharm Corporation Information
11.6.2 Sinopharm Overview
11.6.3 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Sinopharm Recent Developments
11.7 Shanghai RAAS
11.7.1 Shanghai RAAS Corporation Information
11.7.2 Shanghai RAAS Overview
11.7.3 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Shanghai RAAS Recent Developments
11.8 CTBB
11.8.1 CTBB Corporation Information
11.8.2 CTBB Overview
11.8.3 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 CTBB Recent Developments
11.9 Nanyue Biopharming
11.9.1 Nanyue Biopharming Corporation Information
11.9.2 Nanyue Biopharming Overview
11.9.3 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Nanyue Biopharming Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industry Chain Analysis
12.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Production Mode & Process
12.4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales and Marketing
12.4.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Channels
12.4.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors
12.5 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industry Trends
13.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Drivers
13.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Challenges
13.4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Restraints
14 Key Findings in The Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of 1g/20ml
Table 3. Major Manufacturers of 1.25g/25ml
Table 4. Major Manufacturers of 2.5g/50ml
Table 5. Major Manufacturers of 5g/100ml
Table 6. Major Manufacturers of 10g/200ml
Table 7. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2022) & (K Units)
Table 10. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2017-2022)
Table 11. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2023-2028) & (K Units)
Table 12. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2023-2028)
Table 13. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2022) & (US$ Million)
Table 14. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region (2017-2022)
Table 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2023-2028) & (US$ Million)
Table 16. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region (2023-2028)
Table 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Manufacturers (2017-2022) & (K Units)
Table 18. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Manufacturers (2017-2022)
Table 19. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 20. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Manufacturers (2017-2022)
Table 21. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Manufacturers (2017-2022) &(US$/Unit)
Table 22. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) as of 2021)
Table 24. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
Table 26. Date of Manufacturers Enter into Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
Table 29. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units)
Table 30. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Type (2017-2022)
Table 31. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Type (2023-2028)
Table 32. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million)
Table 33. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million)
Table 34. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Type (2017-2022)
Table 35. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Type (2023-2028)
Table 36. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Type (2017-2022) & (US$/Unit)
Table 37. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Forecast by Type (2023-2028) & (US$/Unit)
Table 38. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
Table 39. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units)
Table 40. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Application (2017-2022)
Table 41. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Application (2023-2028)
Table 42. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million)
Table 43. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million)
Table 44. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Application (2017-2022)
Table 45. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Application (2023-2028)
Table 46. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Application (2017-2022) & (US$/Unit)
Table 47. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Forecast by Application (2023-2028) & (US$/Unit)
Table 48. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
Table 49. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units)
Table 50. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million)
Table 51. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million)
Table 52. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
Table 53. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units)
Table 54. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million)
Table 55. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million)
Table 56. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units)
Table 57. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2023-2028) & (K Units)
Table 58. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (US$ Million)
Table 59. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2023-2028) & (US$ Million)
Table 60. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
Table 61. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units)
Table 62. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million)
Table 63. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million)
Table 64. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
Table 65. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units)
Table 66. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million)
Table 67. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million)
Table 68. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units)
Table 69. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2023-2028) & (K Units)
Table 70. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (US$ Million)
Table 71. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2023-2028) & (US$ Million)
Table 72. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
Table 73. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units)
Table 74. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million)
Table 75. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million)
Table 76. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
Table 77. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units)
Table 78. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million)
Table 79. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million)
Table 80. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2022) & (K Units)
Table 81. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2023-2028) & (K Units)
Table 82. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2022) & (US$ Million)
Table 83. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2023-2028) & (US$ Million)
Table 84. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
Table 85. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units)
Table 86. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million)
Table 87. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million)
Table 88. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
Table 89. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units)
Table 90. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million)
Table 91. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million)
Table 92. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units)
Table 93. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2023-2028) & (K Units)
Table 94. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (US$ Million)
Table 95. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2023-2028) & (US$ Million)
Table 96. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
Table 97. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units)
Table 98. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million)
Table 99. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million)
Table 100. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
Table 101. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units)
Table 102. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million)
Table 103. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million)
Table 104. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units)
Table 105. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2023-2028) & (K Units)
Table 106. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (US$ Million)
Table 107. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2023-2028) & (US$ Million)
Table 108. Boya-Bio Corporation Information
Table 109. Boya-Bio Description and Major Businesses
Table 110. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 111. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Boya-Bio Recent Developments
Table 113. Beijing Tiantan Biological Products Corporation Information
Table 114. Beijing Tiantan Biological Products Description and Major Businesses
Table 115. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 116. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Beijing Tiantan Biological Products Recent Developments
Table 118. Hualan Bio Corporation Information
Table 119. Hualan Bio Description and Major Businesses
Table 120. Hualan Bio Human Immunoglo

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs